Article Sidebar
Published:
Feb 7, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Anti-hypertensive effect of <i>Morus alba</i> L extract in rats
Abstract
Purpose: To investigate the probable antihypertensive effects of Morus alba L. extract (MALE) in renovascular hypertensive rats, and the mechanism involved in the reduction of blood pressure.
Methods: The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in Wistar rats. The 2K1C group rats were treated with captopril (30 mg/kg), and Morus alba extract (75 and 150 mg/kg) daily for 6 weeks by intragastric administration. Systolic (SBP) and diastolic blood pressure (DBP) were measured by the tail-cuff method. Urine creatinine and urea of the rats were measured by enzyme-linked immunosorbent assay (ELISA). Superoxide dismutase (SOD) and malondialdehyde (MDA) were also evaluated using standard techniques.
Results: In the captopril- and extract-treated groups, blood pressure decreased progressively over the course of the 6-week treatment period compared with that of the control rats (p < 0.01). The extract at 150 mg/kg also significantly (p < 0.05) increased plasma SOD activity but decreased plasma MDA concentration. Renal function significantly (p < 0.01) improved following captopril and extract (150 mg/kg) treatment.
Conclusion: The results suggest that Morus alba extract exerts its antihypertensive effect in rats by inhibiting endothelin (ET)-converting enzyme and via its antioxidant activity. Thus, the plant extract has some potentials for development into a new drug in for use in humans.
